Background: To explore the application of a creative quantitative measurement of iris angiography (IA) in diabetic retinopathy (DR).
Methods: This was a single-center cross-sectional study. From May 2016 to December 2019, 30 consecutive patients (60 eyes) with severe non-proliferative diabetic retinopathy (NPDR) and 30 consecutive patients (60 eyes) with proliferative diabetic retinopathy (PDR) who underwent IA in Tianjin Medical University Eye Hospital were enrolled prospectively in the study. All of the patients underwent ophthalmologic examination including visual acuity, intraocular pressure, slit-lamp microscopy, slit-lamp anterior lens, ultra-wide-field fundus photography and IA. IA included iris fluorescein angiography (IFA) and iris indocyanine green angiography (IICGA). The onset time of iris vascular leakage should be recorded and the circumference range of pupil margin fluorescein leakage was measured by self-developed software. Independent sample t-test and chi-square test were used to compare and analyze the difference of the onset time and range of iris vascular leakage between severe NPDR and PDR groups.
Results: IFA showed that the onset time of iris vascular leakage was 30.38±6.40s in severe NPDR group and 26.50±5.41s in PDR group. The difference between two groups was statistically significant (p=0.006). The range of iris vascular leakage was 49.09±59.27 degrees in severe NPDR group and 137.71±95.53 degrees in PDR group. There was significant statistically difference between two groups (p=0.032). No neovascularization of the iris (NVI) was found in all patients with PDR by slit-lamp microscope examination, while NVI was detected in 8 eyes by IFA and IICGA examination.
Conclusions: The creative quantitative measurement of IA can evaluate the severity of diabetic iridopathy (DI), monitor the progress of DR, and detect NVI invisible to the naked eye as soon as possible, so as to provide a basis for the formulation of personalized treatment for patients with DR.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
No competing interests reported.
Loading...
Posted 04 Mar, 2021
Posted 04 Mar, 2021
Background: To explore the application of a creative quantitative measurement of iris angiography (IA) in diabetic retinopathy (DR).
Methods: This was a single-center cross-sectional study. From May 2016 to December 2019, 30 consecutive patients (60 eyes) with severe non-proliferative diabetic retinopathy (NPDR) and 30 consecutive patients (60 eyes) with proliferative diabetic retinopathy (PDR) who underwent IA in Tianjin Medical University Eye Hospital were enrolled prospectively in the study. All of the patients underwent ophthalmologic examination including visual acuity, intraocular pressure, slit-lamp microscopy, slit-lamp anterior lens, ultra-wide-field fundus photography and IA. IA included iris fluorescein angiography (IFA) and iris indocyanine green angiography (IICGA). The onset time of iris vascular leakage should be recorded and the circumference range of pupil margin fluorescein leakage was measured by self-developed software. Independent sample t-test and chi-square test were used to compare and analyze the difference of the onset time and range of iris vascular leakage between severe NPDR and PDR groups.
Results: IFA showed that the onset time of iris vascular leakage was 30.38±6.40s in severe NPDR group and 26.50±5.41s in PDR group. The difference between two groups was statistically significant (p=0.006). The range of iris vascular leakage was 49.09±59.27 degrees in severe NPDR group and 137.71±95.53 degrees in PDR group. There was significant statistically difference between two groups (p=0.032). No neovascularization of the iris (NVI) was found in all patients with PDR by slit-lamp microscope examination, while NVI was detected in 8 eyes by IFA and IICGA examination.
Conclusions: The creative quantitative measurement of IA can evaluate the severity of diabetic iridopathy (DI), monitor the progress of DR, and detect NVI invisible to the naked eye as soon as possible, so as to provide a basis for the formulation of personalized treatment for patients with DR.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...